Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging

Cancer Science

Volumn 107, Issue 3, 2016, Pages 347-352

  Wei, Ling ^a   Tominaga, Hideyuki ^b   Ohgaki, Ryuichi ^a   Wiriyasermkul, Pattama ^a   Hagiwara, Kohei ^a   Okuda, Suguru ^a   Kaira, Kyoichi ^c   Oriuchi, Noboru ^b   Nagamori, Shushi ^a   Kanai, Yoshikatsu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amino acid transporter; Biomarker; Molecular probe; PET; Tumor imaging

Indexed keywords

3 FLUORO LEVO ALPHA METHYL TYROSINE; 3 FLUORO LEVO ALPHA METHYL TYROSINE C 13; 3 FLUORO LEVO ALPHA METHYL TYROSINE F 18; ALANINE; AMINO ACID TRANSPORTER; CYSTINE; GLUTAMINE; L TYPE AMINO ACID TRANSPORTER 1; LEUCINE; METHIONINE; METHIONINE C 14; METIROSINE; RADIOPHARMACEUTICAL AGENT; SMALL INTERFERING RNA; TYROSINE; UNCLASSIFIED DRUG; 3-FLUORO-ALPHA-METHYLTYROSINE; TUMOR MARKER;

AMINO ACID TRANSPORT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; OOCYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TUMOR CELL; UPREGULATION; XENOPUS LAEVIS; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BIOMARKERS, TUMOR; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; METHYLTYROSINES; RADIOPHARMACEUTICALS; RNA, SMALL INTERFERING; XENOPUS LAEVIS;

EID: 84959084261     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12878     Document Type: Article

References (34)

1. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med 2008; 49(Suppl 2): 43S-63S.
2. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999; 26: 1363-78.
3. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-45.
4. 11C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998; 25: 629-33.
5. 18F-fluoroethyl)-l-tyrosine. Eur J Nucl Med Mol Imaging 2003; 30: 519-24.
6. 18F-α-methyltyrosine using a separation and purification system. Nucl Med Commun 1997; 18: 169-75.
7. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131: 1019-27.
8. Inoue T, Koyama K, Oriuchi N et al. Detection of malignant tumors: whole-body PET with fluorine 18 α-methyl tyrosine versus FDG-Preliminary study. Radiology 2001; 220: 54-62.
9. Kaira K, Oriuchi N, Otani Y et al. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007; 13: 6369-78.
10. 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 2009; 124: 1152-60.
11. 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma. J Nucl Med 2015; 56: 16-21.
12. 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2013; 40: 1692-700.
13. 18F-α-methyl tyrosine PET. Am J Roentgenol 2010; 195: 1204-11.
14. Suzuki S, Kaira K, Ohshima Y et al. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer 2014; 110: 1985-91.
15. Kanai Y, Segawa H, Miyamoto KI, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-32.
16. Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med 2013; 34: 139-58.
17. Yanagida O, Kanai Y, Chairoungdua A et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
18. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-92.
19. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-8.
20. Kaira K, Sunose Y, Arakawa K et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012; 107: 632-8.
21. Toyoda M, Kaira K, Ohshima Y et al. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2 and xCT) in surgically resected tongue cancer. Br J Cancer 2014; 110: 2506-13.
22. Kaira K, Sunose Y, Ohshima Y et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer 2013; 13: 482.
23. Kaira K, Oriuchi N, Imai H et al. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99: 2380-6.
24. Wang Q, Holst J. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res 2015; 5: 1281-94.
25. Wiriyasermkul P, Nagamori S, Tominaga H et al. Transport of 3-fluoro-l-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med 2012; 53: 1253-61.
26. 11C)tyrosine in human brain using positron emission tomography. Eur J Nucl Med 1987; 13: 288-91.
27. Bröer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008; 88: 249-86.
28. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77.
29. Shikano N, Kawai K, Nakajima S et al. Renal accumulation and excretion of radioiodinated 3-iodo-α-methyl-l-tyrosine. Ann Nucl Med 2004; 18: 263-70.
30. 123I]IMT) transport in human GOS3 glioma cells. Nucl Med Biol 2001; 28: 293-7.
31. Camargo SM, Vuille-dit-Bille RN, Mariotta L et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther 2014; 351: 114-23.
32. Oda K, Hosoda N, Endo H et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 2010; 101: 173-9.
33. Kim DK, Kanai Y, Choi HW et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 2002; 1565: 112-21.
34. 0, +, LAT1 and LAT2. Cancer Sci 2015; 106: 279-86.